Latest News for VRCI
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced it has received clinical laboratory accreditation from the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP). The Company also received NY state approval of Tutivia™, its blood-based laboratory developed test (LDT) that delivers…
FRANKLIN, Tenn.--(BUSINESS WIRE)--Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, today announced the publication of a peer-reviewed clinical validation study of the Pre-Transplant Rejection Assessment (PTRA) test that stratifies patients undergoing deceased donor kidney transplantation as to their risk of acute rejection in the first two months post-transplant. The…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VRCI.
U.S. House Trading
No House trades found for VRCI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.